Printer Friendly

Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an omnicompetent patient. A case study.

Introduction

Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening disease that results from uncontrolled immune activation leading to unrestrained cytokine release and macrophage activation that can lead to multiorgan dysfunction. (1) HLH can present in either the primary or hereditary type, which is most commonly seen in children and young adults, or the secondary or acquired type, which is most commonly encountered in adults and is often triggered by bacterial, viral, fungal or protozoal infections, autoimmune diseases or malignancies. (1,2), If left untreated, HLH carries a high mortality rate of 58% - 75% in adults. (1,3) Its treatment includes identification and treatment of the underlying cause, and in some cases, specific treatment for HLH depending on the etiology, such as dexamethasone, intravenous immunoglobulin (IVIG), etoposide cyclosporine A, and rituximab for infection-associated HLH, cyclosporine, IVIG, and etoposide for malignancy-associated HLH, cyclosporine and anakinra for autoimmune-associated HLH, and cyclosporine and tocilizumab for drug-induced HLH. (4,5) We present the case of a young woman that presented with HLH associated with a concurrent EBV infection.

Case report

A 19-year old Caucasian woman with no significant past medical history presented to the Emergency Department with fever up to 39[degrees]C for 10 days and vomiting. The clinical examination was notable for jaundice and splenomegaly, while laboratory examination revealed abnormal liver chemistry, with an SGOT of 628 U/L (normal range (nr) 0-35 U/L), SGPT of 432 U/L (nr 0-35 U/L), [gamma]GT of 382 U/L (nr 0-38 U/l), ALP 117 (nr 30-120 U/L), total bilirubin of 18.59 mg/dL (nr 0.3-1.2 mg/dL) and direct bilirubin of 10.05 mg/dL (nr 0-0.2 mg/dL), while LDH was 2006 U/mL (nr 0-247 U/L). Hemoglobin was 10.6 g/dL (nr 12-16 g/dL), white blood cells were 14.1 K/[micro]L (nr 3.8-10.5 K/[micro]L) and platelets were 160,000 K/[micro]L (nr 150-450 K/[micro]L). An ultrasound of the upper abdomen revealed mild splenomegaly of 14 cm without any other abnormalities. The patient was admitted and treatment with intravenous levofloxacin and oral doxycycline was initiated and continued for three days. Further laboratory work-up revealed positive IgM and IgG for EBV viral capsid antigen and CMV, while PCR for CMV DNA in the serum was negative and PCR for EBV DNA in the serum was positive with a titer of 5.13* [10.sup.5] copies/mL HAV IgM & IgG, HIV, HBsAg, IgM & IgG HBcAb, anti-HBs, anti-HCV, HCV RNA, HEV RNA, HSV-1 IgM & IgG, HSV-2 IgM & IgG, parvovirus IgM & IgG, adenovirus IgM & IgG, varicella zoster virus IgM & IgG, Leptospira antibodies, PCR for respiratory pathogens were all negative. Blood cultures were positive only twice, however, the patient was febrile during the whole time of her hospitalization, despite treatment with appropriate antimicrobials and sterilization of the blood cultures. IgG against the Epstein-Barr nucleic antigen (EBNA) was negative, thus suggesting acute rather than chronic infection. Table 1 shows the laboratory workup and the antimicrobial treatment of the patient.

On the second hospital day a drop of the hemoglobin level was noted (down to 5 g/dL), and a direct Coombs test was positive (IgM[+ or -], C3d+) while reticulocytes were not increased (1.01%). A peripheral blood smear revealed the presence of activated lymphocytes and aggregation of red cells. Cryoglobulin was positive with a titer of 1:128. On the third hospital day the patient suddenly developed severe hypoxemia refractory to oxygen supplementation and was transferred to the Intensive Care Unit (ICU). An ultrasound of the lungs revealed the presence of bilateral pleural fluid that was tapped and was proved to be an exudate. Due to worsening respiratory function she was intubated on the third hospital day and was treated with high doses of norepinephrine due to fluid resistant hypotension. The fourth hospital day she became anuric and a urine sediment microscopic examination revealed the presence of muddy brown casts, suggesting acute tubular necrosis. Thus, continuous veno-venous hemofiltration was initiated. Further laboratory examination revealed increased triglycerides up to 1,722 mg/dL that persisted despite the discontinuation of propofol infusion. Furthermore, ferritin was increased, with a value of 18,685 ng/mL. During her 19-day stay in the ICU she remained febrile with a fever up to 40[degrees]C and was treated with acyclovir and several courses of antibiotics including tigecycline, daptomycin, meropenem, colistin and micafungin, without improvement. She was also treated with intravenous prednisolone in a dose of 0.7 mg/kg/day, but despite that she developed a maculopapular rash on the face, the torso and the extremities that resolved the following days. Considering the possibility of hemophagocytic lymphohistiocytosis associated with EBV infection, the patient was treated with corticosteroid pulses and intravenous gamma-globulin at a dose of 0.4 gr/kg/day for 5 days. A bone marrow biopsy revealed the presence of hyperplastic bone marrow with many macrophages and evidence of red blood cell phagocytosis, thus confirming the diagnosis of hemophagocytic lymphohistiocytosis. The patient remained intubated for 11 days, and after 19 days of ICU stay, she was transferred to the Internal Medicine Department where she was treated with corticosteroids and intermittent hemodialysis until her renal function was restored and fever subsided, while ferritin and triglycerides were reduced. A computerized tomography (CT) of the thorax and the abdomen was performed and was unrevealing. The patient was discharged after one month of hospitalization and was followed up on an outpatient basis for one year, with no subsequent evidence of relapse or any sign of hematologic, malignant or autoimmune disease.

Discussion

The pathogenesis of secondary HLH involves gene polymorphisms as in primary HLH, as well as factors that trigger the development of the syndrome. EBV infection has been previously described to be a trigger for secondary HLH. In a series of 73 patients with HLH, EBV infection was identified as the causative factor in 5 cases. (1 )EBV can lead to macrophage activation due to the increased production of TNF-[alpha], IFN-[gamma], and other cytokines by the EBV-infected T-cells. (6) On the other hand, EBV-associated HLH could be more frequent in patients with genetic predisposition, such as in patients with ITK deficiency, CD70 deficiency, CD27 deficiency and magnesium transporter 1 (MAGT1) deficiency. (7)

In our case, the patient developed fever, splenomegaly, hypertriglyceridemia, increased levels of ferritin and hemophagocytosis in the bone marrow, as revealed by bone marrow biopsy, fulfilling the diagnostic criteria for diagnosis of HLH, (1) as indicated below - five of the following 8 criteria must be fulfilled:

(1.) Fever

(2.) Splenomegaly

(3.) Bicytopenia or pancytopenia (absolute neutrophil count <1x109/L, hemoglobin <9 g/dL, platelet count <100x109/L)

(4.) Hypertriglyceridemia (>265 mg/dL) and/or hypofibrinogenemia (<150 mg/dL)

(5.) Hemophagocytosis in the bone marrow, spleen or lymph nodes

(6.) Hyperferritinemia (>500 mg/L)

(7.) Elevated soluble IL-2 receptor (>2,400 U/mL)

(8.) Absent or decreased NK cell function

Alternatively, a molecular diagnosis consistent with HLH suffices to establish the diagnosis.

The differential diagnosis of HLH can be broad and includes viral infections, fungal and bacterial infections, hematologic malignancy, autoimmune diseases, primary immunodeficiency, and post solid organ transplantation, but in many cases, no cause is found and HLH is then termed idiopathic. (1,8) In the present case, the patient had an EBV infection, as proved by the positive EBV DNA PCR in the serum. An extensive workup including virology and immunologic workup, blood cultures, a CT of the thorax and the abdomen and a biopsy of the bone marrow did not reveal any other possible cause of secondary HLH. Furthermore, the patient was followed up for one year after discharge and no sign of malignancy or autoimmune disease developed, suggesting that EBV was the only factor that could be associated with the development of secondary HLH. On the other hand, it could be that the patient developed primary HLH that led to reactivation of EBV infection and persistent EBV viremia, even though this scenario seems unlikely due to the negative IgG EBNA that implies that EBV infection was acute, rather than chronic. (7) To that end, even though the patient had not had an episode of HLH beforehand, the follow-up period after the episode had been one year, thus, the possibility of a relapse of HLH exists, even though a relapse of HLH would not necessarily mean that HLH was primary, but could also be secondary to another stimulus.

The mortality of HLH, if left untreated, is 95% with a very poor survival of less than 2 months; thus, early recognition of this fatal disorder is critical in order to reduce mortality. (2 )The HLH-94 protocol recommended treatment with intravenous dexamethasone and etoposide, while treatment with cyclosporine is also suggested from the HLH-2004 in order to reduce the possibility of relapse. (9) However, according to newer recommendations, dexamethasone, etoposide and cyclosporine are reserved for primary HLH and for cases of secondary HLH that does not respond to treatment of the underlying cause. (5) Our patient was treated with intravenous corticosteroids and immunoglobulin based on reports of cases that were successfully treated with intravenous immunoglobulin. (10-14 )Although acyclovir has not been associated with a clear clinical benefit in patients with infectious mononucleosis, treatment with intravenous acyclovir was added to the immunosuppressive therapy in order to reduce the viral load of EBV. (15,16)

This case study has some limitations that should be acknowledged. First of all, the patient was considered to be immunocompetent based on the lack of a past medical history suggesting immunosuppression, the lack of previous immunosuppressive treatment, and the absence of a concurrent diagnosis that could suggest impaired immune responses. However, it could be that the patient had defective cytotoxic lymphocyte activity that could have been diagnosed based on natural killer (NK) cell assays; however, these assays were not performed in our patient. Thus, the possibility of a concealed immunosuppression due to defective cytotoxic cell activity cannot be ruled out. Furthermore, the possibility of genetic (primary) HLH leading to reactivation of an EBV infection cannot be definitively ruled out, since genetic testing was not performed, even though the negative IgG EBNA makes this scenario unlikely. Thus, the diagnosis of secondary HLH due to EBV infection is not the only possible diagnosis in this case.

Conclusions

We have presented a rare case of HLH leading to multiple-organ failure that was associated with EBV and was successfully treated with acyclovir, high dose corticosteroids and intravenous immunoglobulin. In patients with EBV infection who exhibit persistently high fever and unresponsiveness to antibiotics, the possibility of HLH should be considered. Early diagnosis and rapid initiation of appropriate treatment may avert an unfavorable outcome.

Consent: Written informed consent was obtained from the patient for publication of this case report.

Authors' contributions statement: PI, EA, KA, AP and ES collected the data and wrote the manuscript. MP, MK, EK, and DPK critically reviewed the manuscript. All authors read and approved the final version of the manuscript.

Conflicts of interest: All authors - none to declare.

Funding: None to declare.

References

(1.) Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90:220-4. https://doi.org/10.1002/ajh.23911

(2.) Tothova Z, Berliner N. Hemophagocytic syndrome and critical illness: new insights into diagnosis and management. J Intensive Care Med. 2015;30:401-12. https://doi.org/10.1177/0885066613517076

(3.) George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014;5:69-86. https://doi.org/10.2147/JBM.S46255

(4.) Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-31. https://doi.org/10.1002/pbc.21039

(5.) La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133:2465-77. https://doi.org/10.1182/blood.2018894618

(6.) Lay JD, Chuang SE, Rowe M, Su IJ. Epstein-barr virus latent membrane protein-1 mediates upregulation of tumor necrosis factor-alpha in EBV-infected T cells: implications for the pathogenesis of hemophagocytic syndrome. J Biomed Sci. 2003;10:146-55. https://doi.org/10.1159/000068077

(7.) Marsh RA. Epstein-Barr virus and hemophagocytic lymphohistiocytosis. Front Immunol. 2018;8:1902. https://doi.org/10.3389/fimmu.2017.01902

(8.) Kofteridis DP, Koulentaki M, Valachis A, et al. Epstein Barr virus hepatitis. Eur J Intern Med. 2011;22:73-6. https://doi.org/10.1016/j.ejim.2010.07.016

(9.) Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125:2908-14. https://doi.org/10.1182/blood-2015-01-551622

(10.) Ostronoff M, Ostronoff F, Coutinho M, et al. Hemophagocytic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma; successful treatment with high-dose intravenous immunoglobulin. Bone Marrow Transplant. 2006;37:797-8. https://doi.org/10.1038/sj.bmt.1705329

(11.) Hot A, Madoux MH, Viard JP, Coppere B, Ninet J. Successful treatment of cytomegalovirus-associated hemophagocytic syndrome by intravenous immunoglobulins. Am J Hematol. 2008;83:159-62. https://doi.org/10.1002/ajh.21008

(12.) La Rosee P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc Hematol Educ Program. 2015;2015:190-6. https://doi.org/10.1182/asheducation-2015.1.190

(13.) Larroche C, Bruneel F, Andre MH, et al. [Intravenously administered gamma-globulins in reactive hemaphagocytic syndrome. Multicenter study to assess their importance, by the immunoglobulins group of experts of CEDIT of the AP-HP]. Ann Med Interne (Paris). 2000;151:533-9.

(14.) Emmenegger U, Spaeth PJ, Neftel KA. Intravenous immunoglobulin for hemophagocytic lymphohistiocytosis? J Clin Oncol. 2002;20:599-601. https://doi.org/10.1200/JCO.2002.20.2.599

(15.) De Paor M, O'Brien K, Fahey T, Smith SM. Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database Syst Rev. 2016;12:CD011487. https://doi.org/10.1002/14651858.CD011487.pub2

(16.) Tynell E, Aurelius E, Brandell A, et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J Infect Dis. 1996;174:324-31. https://doi.org/10.1093/infdis/174.2.324

Please cite this article as: Ioannou P, Akoumianaki E, Alexakis K, Proklou A, Psyllaki M, Stamatopoulos E, Koulentaki M, Kondili E, Kofteridis DP. Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an omnicompetent patient. A case study. GERMS. 2020;10(3):266-271. doi: 10.18683/germs.2020.1216

Petros Ioannou (1,*), Evangelia Akoumianaki (2), Konstantinos Alexakis (3), Athanasia Proklou (4), Maria Psyllaki (5), Efthimis Stamatopoulos (6), Mairi Koulentaki (7), Eumorfia Kondili (8), Diamantis P Kofteridis (9)

Received: 27 April 2020; revised: 04 July 2020; accepted: 16 July 2020.

(1) MD, MSc, PhD, Department of Internal Medicine, University Hospital of Heraklion, Stavrakia and Voutes crossroad, Heraklion, PC 71110, Crete, Greece; (2) MD, PhD, Intensive Care Unit, University Hospital of Heraklion, Stavrakia and Voutes crossroad, Heraklion, PC 71110, Crete, Greece; (3) MD, Department of Internal Medicine, University Hospital of Heraklion, Stavrakia and Voutes crossroad, Heraklion, PC 71110, Crete, Greece; (4) MD, PhD, Intensive Care Unit, University Hospital of Heraklion, Stavrakia and Voutes crossroad, Heraklion, PC 71110, Crete, Greece; (5) MD, PhD, Department of Hematology, University Hospital of Heraklion, Stavrakia and Voutes crossroad, Heraklion, PC 71110, Crete, Greece; (6) MD, Department of Gastroenterology, University Hospital of Heraklion, Stavrakia and Voutes crossroad, Heraklion, PC 71110, Crete, Greece; (7) MD, PhD, Department of Gastroenterology, University Hospital of Heraklion, Stavrakia and Voutes crossroad, Heraklion, PC 71110, Crete, Greece; (8) MD, PhD, Intensive Care Unit, University Hospital of Heraklion, Stavrakia and Voutes crossroad, Heraklion, PC 71110, Crete, Greece; (9) MD, PhD, Department of Internal Medicine, University Hospital of Heraklion, Stavrakia and Voutes crossroad, Heraklion, PC 71110, Crete, Greece.

(*) Corresponding author: Petros Ioannou, p.ioannou@med.uoc.gr
Table 1. Laboratory course and antimicrobial treatment of the patient

Day  CRP      WBC          Hb      Antimicrobial        Blood
     (mg/dL)  (/[micro]L)  (g/dL)  therapy              cultures

ED            13,100       12.6     Doxy+levofl
1    15       14,100        8.8     Doxy+levofl
2             26,100        5       Doxy+levofl
3    19       26,100        8       Tigecycline
4             36,000        7.2     Tigecycline
5             20,600        7.6     Meropenem
6    10       15,700        8.1     Meropenem
7             12,700        8.8     Meropenem
8               8300        8.3     Meropenem
9    1.88     10,100        8.1     Meropenem
10             8,000        7.6     Meropenem            A. baumannii
11            11,800        8.5     Colistin
12            18,000        8       Colistin
13   13.7     22,000        8       Colistin
14            22,300        6.2     Colistin
15            16,400        7.2     Colistin
16   19.8     18,100        7.8     Colistin             S. epidermidis
17            19,100        7       Dapto+colistin+mica
18            16,700        8.7     Dapto+colistin+mica
19            17,100        9.2     Dapto+colistin+mica
20            13,500        7.3     Dapto+colistin+mica
21   12.2     11,000        7.5     Dapto+colistin+mica
22   28       12,600        9.1     Dapto+colistin+mica
23            11,700        8.8     Dapto+colistin+mica
24   6.65     14,400        9.2     Dapto+colistin+mica
25            13,800        8.8     Dapto+colistin+mica
26            16,800        8.6     Dapto+colistin+mica
27   3.55     13,900        8.2     Dapto+colistin+mica
28            19,200        8.1     Dapto+colistin+mica
29                                  Dapto+colistin+mica
30   2.68     22,200        8.7     Dapto+colistin+mica

Day  PCR EBV       EBV VCA     EBV VCA
     (copies /mL)  IgM (U/mL)  IgG (U/mL)

ED
1                  12.4        1.42
2
3    5.13x105
4
5
6
7
8
9
10
11
12
13                 64.6        38.8
14
15
16
17   4.73x105
18
19
20
21
22
23
24
25
26
27
28
29
30

CRP - C reactive protein; Dapto - daptomycin; doxy - doxycycline;
EBV - Epstein-Barr virus; ED - Emergency Department; Hb - hemoglobin;
levofl - levofloxacin; mica - micafungin; VCA - viral capsid antigen;
WBC - white blood cell count.
COPYRIGHT 2020 Asociatia pentru Cresterea Vizibilitatii Cercetarii Stiintifice (ACVCS)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Case report
Author:Ioannou, Petros; Akoumianaki, Evangelia; Alexakis, Konstantinos; Proklou, Athanasia; Psyllaki, Maria
Publication:GERMS
Geographic Code:4EUGR
Date:Sep 1, 2020
Words:2950
Previous Article:Severe scarlet fever in a child with Down syndrome - a case report.
Next Article:Comment on: "The relationship between the exposure to healthcare settings and colonization with methicillin-resistant Staphylococcu s aureu s among...
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters